Incyte CORP Form 4 insider transactions

An Incyte executive exercised stock options and immediately sold the acquired shares under a pre-arranged trading plan.

Incyte's EVP & Chief Medical Officer, Steven H. Stein, sold 3,706 shares of common stock at $67.94 per share under a Rule 10b5-1 trading plan.

Incyte Corp's EVP & General Manager US, Barry P Flannelly, sold 1,340 shares of common stock for $68.36 per share under a Rule 10b5-1 trading plan.

Incyte Corp's EVP, Vijay K Iyengar, has filed a Form 4 indicating a future sale of 983 common shares on July 16, 2025, under a pre-arranged Rule 10b5-1 plan.

Incyte Corporation's EVP & General Counsel, Sheila A. Denton, reported multiple transactions including stock option exercises, sales of common stock, and significant new equity awards on July 15 and 16, 2025.

Mohamed Khairie Issa, Incyte Corporation's EVP and Head of US Oncology, was granted a significant equity award package comprising restricted stock units, performance shares, and stock options on July 15, 2025.

Incyte Corporation's EVP and General Manager of US Dermatology, Matteo Trotta, reported new grants of restricted stock units, performance shares, and stock options, alongside a disposition of shares for tax withholding.

Incyte Corp's EVP, Head of Incyte International, Lee Heeson, was granted 6,577 performance shares on July 15, 2025, which can yield up to 200% of common stock based on the company's relative total shareholder return over a three-year period.

Incyte Corp's EVP, Head of Tech. Operations, Michael James Morrissey, was granted 10,961 performance shares, which can yield up to 200% of common stock based on the company's relative total shareholder return over a three-year period.

Incyte Corporation's President of R&D, Pablo J. Cagnoni, has filed a Form 4 detailing future equity awards including restricted stock units, performance shares, and stock options, alongside tax-related share dispositions, all scheduled for mid-July 2025.

Incyte Corporation's EVP & Chief Medical Officer, Steven H. Stein, reported the sale of common stock and the acquisition of new restricted stock units, performance shares, and employee stock options.

Paula J. Swain, Executive Vice President of Human Resources at Incyte Corp, reported the acquisition of new restricted stock units, performance shares, and stock options, alongside the disposition of shares for tax withholding purposes.

Incyte Corporation's EVP & Chief Financial Officer, Christiana Stamoulis, reported the acquisition of substantial restricted stock units, performance shares, and stock options, alongside tax-related dispositions of common stock.

Incyte Corp's Principal Accounting Officer, Thomas Tray, reported the acquisition of restricted stock units and employee stock options, alongside shares withheld for tax obligations.

Incyte Corporation's EVP, Vijay K Iyengar, reported a series of equity transactions including the acquisition of restricted stock units, performance shares, and stock options, alongside routine sales and tax-related dispositions.

An Incyte Corp executive, Barry P. Flannelly, EVP & General Manager US, disposed of 3,255 shares of common stock through pre-planned sales and tax withholdings in mid-July 2025.

Herve Hoppenot, a Director and Special Advisor to the CEO of Incyte Corp, reported the disposition of shares to cover tax withholding obligations related to previously vested equity awards.

Incyte Corp's EVP of Human Resources, Paula J. Swain, reported the disposition of 6,285 common shares at $68.17 per share to cover tax withholding obligations related to previously vested equity.

Incyte Corp's Principal Accounting Officer, Tray Thomas, reported the disposition of 897 shares of common stock to cover tax withholding obligations related to restricted stock units.

Steven H. Stein, Incyte's EVP & Chief Medical Officer, reported a future disposition of 12,714 common shares on July 2, 2025, to cover tax withholding obligations related to equity awards under a Rule 10b5-1 plan.

Incyte Corporation's EVP & Chief Financial Officer, Christiana Stamoulis, reported a routine disposition of 11,589 shares of common stock to satisfy tax withholding obligations related to vested equity, with her beneficial ownership now totaling 117,504 shares.

Barry P Flannelly, EVP & General Manager US of Incyte Corp, reported the withholding of shares for tax obligations and a pre-planned sale of common stock.

Incyte Corporation's Executive Vice President and General Counsel, Sheila A. Denton, engaged in a pre-planned transaction involving the exercise of stock options and the subsequent sale of common stock on July 2, 2025.

Incyte Corporation's Executive Vice President, Vijay K. Iyengar, reported the sale of 15,426 shares of common stock in early July 2025, including shares withheld for tax obligations, all executed under a Rule 10b5-1 trading plan.

Incyte Corp's Director and Special Advisor to the CEO, Herve Hoppenot, reported a pre-planned disposition of 42,769 common shares at $68.17 per share scheduled for July 2, 2025, primarily for tax withholding related to RSU and performance share settlements.

Julian C. Baker, a director of Incyte Corporation and representative of Baker Bros. entities, received 492 shares of Incyte common stock as quarterly director retainer fees, leading to updated beneficial ownership disclosures for associated funds and individuals.

Incyte Corporation Director Paul J. Clancy acquired 361 shares of common stock at $68.10 per share on June 30, 2025, as part of his director compensation.

Incyte Corp. Director Edmund Harrigan acquired 367 shares of common stock at $68.10 per share on June 30, 2025, as part of his quarterly director retainer fees under a Rule 10b5-1 plan.

Mohamed Khairie Issa, EVP, Head of US Oncology at Incyte Corp, was granted 27,812 restricted stock units, increasing his total unvested RSU holdings to 76,483 shares.

Incyte Corporation's Chief Executive Officer, William Meury, was granted 36,101 restricted stock units and performance shares totaling up to 233,303 common shares, contingent on performance and vesting conditions.